Click here to listen to Charles's and other VIRAMUNE patients' inspiring stories.

The Viramune® (nevirapine) tablets/oral suspension
Co-Pay Savings Card Program

The Viramune Co-Pay Savings Card Program offers you savings of up to $50 toward your monthly co-pay for up to 12 months on each VIRAMUNE prescription. You can get a VIRAMUNE Co-Pay Savings Card from your doctor along with your prescription for VIRAMUNE.
Then, all you have to do is present it to any pharmacy (including mail-order pharmacies) that accepts MasterCard®.

The VIRAMUNE Co-Pay Savings Card Program can help you save up to $50 per month

Here's how it works:

  • The program provides you with a reduction of up to $50 off the co-pay of each monthly prescription of VIRAMUNE for up to 12 months. You will receive immediate savings on your VIRAMUNE prescription (new and pre-existing) and your refills
  • Simply ask for a VIRAMUNE Co-Pay Savings Card from your doctor when you are given a prescription for VIRAMUNE
  • Once your co-pay card is activated, just present it, plus the required Pharmacist Information and your prescription for VIRAMUNE, to any pharmacy that accepts MasterCard®—no additional paperwork is required
  • You can also enroll in the free Vlife on Therapy™ health and support program
  • Each co-pay debit card comes with a help desk phone number. If you have any questions regarding the program, please call
    1-877-411-8641

Terms and Conditions
This program expires on 12/31/2011. This offer is not valid for patients participating in Medicare, Medicaid, any other federal- or state-funded benefit programs, or where prohibited by law. Cash-paying customers are also not eligible for this offer. Offer good in the United States (including the District of Columbia and Puerto Rico) only.

Boehringer Ingelheim reserves the right to change the terms and conditions of this offer at any point. The VIRAMUNE Co-Pay Savings Card is issued by KeyBank pursuant to the license by MasterCard International Incorporated.

For cardholder service, please call the Macaluso Group at 1-877-411-8641 between 9 am and 5 pm ET, Monday through Friday, except holidays. The issuers shall not be liable to the users for losses, expenses, claims, or other damages that the user may incur as a result of this card.

INDICATION AND IMPORTANT SAFETY INFORMATION

VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination.

VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Ask your healthcare provider about how to recognize symptoms of skin and liver problems.

Stop taking VIRAMUNE if you have any of these reactions. Do not restart VIRAMUNE if you experience any of these reactions. Call your healthcare provider immediately if you have any of these reactions.

VIRAMUNE is only for people diagnosed with HIV. If you have not been diagnosed as HIV positive, then do not take VIRAMUNE.

Any patient can experience liver problems with VIRAMUNE, but women and patients who have higher CD4 counts when they begin VIRAMUNE treatment have a greater risk. If you are a woman with CD4+ >250 cells/mm3, or a man with CD4+ >400 cells/mm3, you should not begin taking VIRAMUNE unless you and your doctor have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk.

Do not take VIRAMUNE if you have severe liver problems.

The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days, followed by one 200-mg tablet twice daily. VIRAMUNE is always taken with other anti-HIV medications. The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. If you have a skin rash during the first 14 days, immediately contact your doctor and do not increase your VIRAMUNE dose to twice a day. The total duration of the once daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started.

Other side effects that patients have experienced include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Changes in body fat may occur in patients receiving antiretroviral therapy. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION AND IMPORTANT SAFETY INFORMATION

VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination.

VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Ask your healthcare provider about how to recognize symptoms of skin and liver problems.

Stop taking VIRAMUNE if you have any of these reactions. Do not restart VIRAMUNE if you experience any of these reactions. Call your healthcare provider immediately if you have any of these reactions.

VIRAMUNE is only for people diagnosed with HIV. If you have not been diagnosed as HIV positive, then do not take VIRAMUNE.

Any patient can experience liver problems with VIRAMUNE, but women and patients who have higher CD4 counts when they begin VIRAMUNE treatment have a greater risk. If you are a woman with CD4+ >250 cells/mm3, or a man with CD4+ >400 cells/mm3, you should not begin taking VIRAMUNE unless you and your doctor have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk.

Do not take VIRAMUNE if you have severe liver problems.

The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days, followed by one 200-mg tablet twice daily. VIRAMUNE is always taken with other anti-HIV medications. The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. If you have a skin rash during the first 14 days, immediately contact your doctor and do not increase your VIRAMUNE dose to twice a day. The total duration of the once daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started.

Other side effects that patients have experienced include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Changes in body fat may occur in patients receiving antiretroviral therapy. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including boxed WARNING and Medication Guide, for VIRAMUNE.